v3.25.2
Disaggregated Revenues
 6 Months Ended
Jun. 30, 2025
Disaggregation of Revenue [Abstract]  
Disaggregated Revenues Disaggregated Revenues
The following table provides information regarding total revenues (dollars in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
(unaudited)(unaudited)
Net product sales
Qelbree$77,547 $59,395 $142,292 $104,499 
GOCOVRI36,660 31,703 67,349 58,265 
APOKYN12,820 17,295 27,796 33,944 
Trokendi XR11,193 17,086 23,994 33,075 
Oxtellar XR11,637 29,516 21,835 56,459 
ONAPGO1,604 — 1,604 — 
Other(1)
6,534 7,543 15,113 14,757 
Total net product sales157,995 162,538 299,983 300,999 
Royalty, licensing and other revenues7,458 5,787 15,294 10,970 
Total revenues$165,453 $168,325 $315,277 $311,969 
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
In the second quarter of 2025, the Company continued to have favorable actual returns experience for Qelbree. As such, the Company changed its estimated provision for product returns based on the most recent experience. Provision for product returns related to prior year sales for the six months period ended June 30, 2025 is approximately 4% of net product sales primarily attributable to Qelbree. Provision for product returns related to prior year sales for the six months period ended June 30, 2024 was approximately 1% of net product sales.